{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:31:20Z","timestamp":1792791080391,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Click Therapeutics, Inc.","id":[{"id":"https:\/\/ror.org\/05frdy048","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-026-02675-6","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:53:53Z","timestamp":1778676833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated analysis of two randomized controlled trials of a digital therapeutic for episodic migraine prevention"],"prefix":"10.1038","volume":"9","author":[{"given":"Shaheen E.","family":"Lakhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Snipes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Peters-Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olya","family":"Besedina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Taraboanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viveca","family":"Livezey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Speier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merle","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart J.","family":"Tepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2675_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111557","volume":"139","author":"J Khan","year":"2021","unstructured":"Khan, J. et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed. Pharmacother. 139, 111557 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"2675_CR2","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1007\/s11606-020-06539-x","volume":"36","author":"D Langenbahn","year":"2021","unstructured":"Langenbahn, D. et al. Underuse of behavioral treatments for headache: a narrative review examining societal and cultural factors. J. Gen. Intern. Med. 36, 3103\u20133112 (2021).","journal-title":"J. Gen. Intern. Med."},{"key":"2675_CR3","first-page":"e28347","volume":"14","author":"J Gupta","year":"2022","unstructured":"Gupta, J. & Gaurkar, S. S. Migraine: an underestimated neurological condition affecting billions. Cureus 14, e28347 (2022).","journal-title":"Cureus"},{"key":"2675_CR4","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1523\/JNEUROSCI.0373-15.2015","volume":"35","author":"R Burstein","year":"2015","unstructured":"Burstein, R., Noseda, R. & Borsook, D. Migraine: multiple processes, complex pathophysiology. J. Neurosci. 35, 6619\u20136629 (2015).","journal-title":"J. Neurosci."},{"key":"2675_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani, J., Burch, R. C. & Robbins, M. S. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 61, 1021\u20131039 (2021).","journal-title":"Headache"},{"key":"2675_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner, T. J. et al. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J. Headache Pain 21, 137 (2020).","journal-title":"J. Headache Pain"},{"key":"2675_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/WCO.0b013e328360edb1","volume":"26","author":"TJ Schwedt","year":"2013","unstructured":"Schwedt, T. J. Multisensory integration in migraine. Curr. Opin. Neurol. 26, 248\u2013253 (2013).","journal-title":"Curr. Opin. Neurol."},{"key":"2675_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01371-y","volume":"23","author":"N Meylakh","year":"2022","unstructured":"Meylakh, N. & Henderson, L. A. Exploring alterations in sensory pathways in migraine. J. Headache Pain 23, 5 (2022).","journal-title":"J. Headache Pain"},{"key":"2675_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03732-x","volume":"24","author":"DC Buse","year":"2024","unstructured":"Buse, D. C. et al. Headache\/migraine-related stigma, quality of life, disability, and most bothersome symptom in adults with current versus previous high-frequency headache\/migraine and medication overuse: results of the Migraine Report Card survey. BMC Neurol. 24, 232 (2024).","journal-title":"BMC Neurol."},{"key":"2675_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2022.100408","volume":"27","author":"O Begasse de Dhaem","year":"2022","unstructured":"Begasse de Dhaem, O. & Sakai, F. Migraine in the workplace. eNeurologicalSci 27, 100408 (2022).","journal-title":"eNeurologicalSci"},{"key":"2675_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles, A. C. et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache 64, 333\u2013341 (2024).","journal-title":"Headache"},{"key":"2675_CR12","unstructured":"Pfizer Inc. NURTEC ODT (rimegepant) [package insert]. New York, NY: Pfizer Inc.; 2026. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/212728s029lbl.pdf."},{"key":"2675_CR13","unstructured":"AbbVie Inc. QULIPTA (atogepant) [package insert]. North Chicago, IL: AbbVie Inc.; 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215206s013lbl.pdf."},{"key":"2675_CR14","unstructured":"Teva Pharmaceuticals USA, Inc. AJOVY (fremanezumab-vfrm) [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761089s031lbl.pdf."},{"key":"2675_CR15","unstructured":"Amgen Inc. AIMOVIG (erenumab-aooe) [package insert]. Thousand Oaks, CA: Amgen Inc.; 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761077s026lbl.pdf."},{"key":"2675_CR16","unstructured":"Eli Lilly and Company. EMGALITY (galcanezumab-gnlm) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761063s010lbl.pdf."},{"key":"2675_CR17","unstructured":"Lundbeck Seattle BioPharmaceuticals, Inc. VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.; 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761119s011lbl.pdf."},{"key":"2675_CR18","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1515\/med-2022-0598","volume":"17","author":"F Haghdoost","year":"2022","unstructured":"Haghdoost, F. & Togha, M. Migraine management: non-pharmacological points for patients and health care professionals. Open Med. 17, 1869\u20131882 (2022).","journal-title":"Open Med."},{"key":"2675_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-015-0500-5","volume":"19","author":"DB Penzien","year":"2015","unstructured":"Penzien, D. B. et al. Well-established and empirically supported behavioral treatments for migraine. Curr. Pain Headache Rep. 19, 34 (2015).","journal-title":"Curr. Pain Headache Rep."},{"key":"2675_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","volume":"80","author":"J Schoenen","year":"2013","unstructured":"Schoenen, J. et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80, 697\u2013704 (2013).","journal-title":"Neurology"},{"key":"2675_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16414","volume":"31","author":"A M\u00ednguez-Olaondo","year":"2024","unstructured":"M\u00ednguez-Olaondo, A. et al. Behavioral therapy in migraine: expanding the therapeutic arsenal. Eur. J. Neurol. 31, e16414 (2024).","journal-title":"Eur. J. Neurol."},{"key":"2675_CR22","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.12154","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton, R. B. et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache 53, 1300\u20131311 (2013).","journal-title":"Headache"},{"key":"2675_CR23","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1111\/head.13838","volume":"60","author":"H Huang","year":"2020","unstructured":"Huang, H. & Minen, M. T. Eleven reasons people decide to choose headache medicine: There may be a headache medicine provider shortage but there are ways to foster interest. Headache 60, 1846\u20131852 (2020).","journal-title":"Headache"},{"key":"2675_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-023-02650-7","volume":"41","author":"E Bentivegna","year":"2024","unstructured":"Bentivegna, E. et al. Unmet needs in the acute treatment of migraine. Adv. Ther. 41, 1\u201313 (2024).","journal-title":"Adv. Ther."},{"key":"2675_CR25","unstructured":"Click Therapeutics announces CT-132 met primary endpoint for the reduction of monthly migraine days in ReMMi-D pivotal trial. Press release. Click Therapeutics. https:\/\/www.clicktherapeutics.com\/press\/click-therapeutics-announces-ct-132-met-primary-endpoint-for-the-reduction\/ (2024)."},{"key":"2675_CR26","doi-asserted-by":"publisher","first-page":"e64959","DOI":"10.2196\/64959","volume":"12","author":"C Snipes","year":"2025","unstructured":"Snipes, C. et al. Establishment and maintenance of a digital therapeutic alliance in people living with negative symptoms of schizophrenia: two exploratory single-arm studies. JMIR Ment. Health 12, e64959 (2025).","journal-title":"JMIR Ment. Health"},{"key":"2675_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1037\/h0085885","volume":"16","author":"E Bordin","year":"1979","unstructured":"Bordin, E. The generalizability of the psychoanalytic concept of the working alliance. Psychother. Theory Res. Pract. 16, 252\u2013260 (1979).","journal-title":"Psychother. Theory Res. Pract."},{"key":"2675_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/wps.20238","volume":"14","author":"BE Wampold","year":"2015","unstructured":"Wampold, B. E. How important are the common factors in psychotherapy? An update. World Psychiatry 14, 270\u2013277 (2015).","journal-title":"World Psychiatry"},{"key":"2675_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1526-4610.2001.01156.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton, R. B. et al. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 41, 854\u2013861 (2001).","journal-title":"Headache"},{"key":"2675_CR30","first-page":"76","volume":"19","author":"M Togha","year":"2020","unstructured":"Togha, M. et al. Estimating quality of life in a headache referral population based on migraine disability assessment scale and headache impact test. Curr. J. Neurol. 19, 76\u201384 (2020).","journal-title":"Curr. J. Neurol."},{"key":"2675_CR31","unstructured":"Lew, C. & Punnapuzha, S. Migraine medications. In: StatPearls [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553159\/ (StatPearls Publishing, 2025)."},{"key":"2675_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt, A. K. et al. Diagnosis and management of migraine in ten steps. Nat. Rev. Neurol. 17, 501\u2013514 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"2675_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41746-023-00777-z","volume":"6","author":"C Wang","year":"2023","unstructured":"Wang, C., Lee, C. & Shin, H. Digital therapeutics from bench to bedside. npj Digit. Med. 6, 38 (2023).","journal-title":"npj Digit. Med."},{"key":"2675_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2023.1086219","volume":"5","author":"A Watson","year":"2023","unstructured":"Watson, A. et al. FDA regulations and prescription digital therapeutics: evolving with the technologies they regulate. Front. Digit. Health 5, 1086219 (2023).","journal-title":"Front. Digit. Health"},{"key":"2675_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2023.1193920","volume":"5","author":"CC Rogers","year":"2023","unstructured":"Rogers, C. C. et al. Designing mobile health to align with the social determinants of health. Front. Digit. Health 5, 1193920 (2023).","journal-title":"Front. Digit. Health"},{"key":"2675_CR36","doi-asserted-by":"publisher","first-page":"e51980","DOI":"10.2196\/51980","volume":"10","author":"Y Sharma","year":"2024","unstructured":"Sharma, Y., Saha, A. & Goldsack, J. C. Defining the dimensions of diversity to promote inclusion in the digital era of health care: a lexicon. JMIR Public Health Surveill. 10, e51980 (2024).","journal-title":"JMIR Public Health Surveill."},{"key":"2675_CR37","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","volume":"87","author":"MT Minen","year":"2016","unstructured":"Minen, M. T. et al. Migraine and its psychiatric comorbidities. J. Neurol. Neurosurg. Psychiatry 87, 741\u2013749 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2675_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1090878","volume":"14","author":"S Duan","year":"2023","unstructured":"Duan, S. et al. Associations between anxiety, depression with migraine, and migraine-related burdens. Front. Neurol. 14, 1090878 (2023).","journal-title":"Front. Neurol."},{"key":"2675_CR39","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/j.1526-4610.2006.00576.x","volume":"46","author":"SW Hamelsky","year":"2006","unstructured":"Hamelsky, S. W. & Lipton, R. B. Psychiatric comorbidity of migraine. Headache 46, 1327\u20131333 (2006).","journal-title":"Headache"},{"key":"2675_CR40","unstructured":"U.S. Food and Drug A. Regulatory considerations for prescription drug use-related software. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/regulatory-considerations-prescription-drug-use-related-software (2023)."},{"key":"2675_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/head.13018","volume":"57","author":"NM Robbins","year":"2017","unstructured":"Robbins, N. M. & Bernat, J. L. Minority representation in migraine treatment trials. Headache 57, 525\u2013533 (2017).","journal-title":"Headache"},{"key":"2675_CR42","doi-asserted-by":"crossref","unstructured":"Snipes, C. et al. Efficacy and safety of a first-in-class investigational prescription digital therapeutic for episodic migraine (CT-132): phase 3 double-blind, randomized, controlled trial. In Proc. American Academy of Neurology Annual Meeting (2025).","DOI":"10.1212\/WNL.0000000000210426"},{"key":"2675_CR43","doi-asserted-by":"crossref","unstructured":"Charles, A. C. et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache 64, 333\u2013341 (2024).","DOI":"10.1111\/head.14692"},{"key":"2675_CR44","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38, 1\u2013211 (2018).","DOI":"10.1177\/0333102417738202"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02675-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:49:29Z","timestamp":1784846969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02675-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2675"],"URL":"https:\/\/doi.org\/10.1038\/s41746-026-02675-6","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.E.L., M.P., C.S., A.K., T.P.-S., O.B., L.T., V.L., and A.S. were employees of Click Therapeutics, Inc. at the time of the study or are current employees. M.D. and S.J.T. serve as advisors for Click Therapeutics Inc. C.S. is an inventor on a patent related to an aspect of the CT-132 treatment, platforms for dynamically selecting messages in real-time to users via decision support tools, which was filed by Click Therapeutics, Inc., and is currently pending (EP4607535A3). S.J.T. has served as a speaker for AbbVie, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Pfizer, Scilex, Teva, and Tonix. He has received honoraria for CME content from the American Academy of Neurology, American Headache Society, Annenberg Center for Health Sciences, Catamount Medical Education, Consortium for Research Education Social Awareness and Training In Neurosciences, Diamond Education Foundation, Forefront Collaborative, Haymarket Medical Education, HMP Global, Medical Education Speakers Network, Medical Learning Institute Peerview, Migraine Association of Ireland, Miller Medical Education, National Association for Continuing Education, North American Center for CME, The Ohio State University, Physicians\u2019 Education Resource, PlatformQ Education, Primed, Vindico Medical Education, and WebMD\/Medscape. He has received research funding from AbbVie, Aeon, Amgen, Annovis, Axsome, Cassava, Cognition, Eli Lilly, Inhibikase, Ipsen, Lundbeck, Merz, Neurolief, Pfizer, PrecisionMed, Revance, Scilex, Suven, and UCB. He has served as consultant and\/or on advisory boards for AbbVie, Aeon, Alphasights, Amgen, Aruene\/eNeura, Atheneum, Axsome Therapeutics, Bausch Health, Becker Pharmaceutical Consulting, Catch Therapeutics, ClearView Healthcare Partners, Click Therapeutics, CoolTech, CRG, Decision Resources, Defined Health, DRG, DocDelta, Dr. Reddy\u2019s, Eli Lilly, ExpertConnect, FCB Health, Fenix, Gilmartin Capital, GLG, Guidepoint Global, Health Advances, Health Science Communications, HMP Communications, Impel, Initiator Pharma, InteractiveForums, IQVIA, Keyquest, Ki Health Partners, Krog and Partners, Lundbeck, M3Global Research, Magellan Health, Magnolia Innovation, Miravo Healthcare, MJH Holdings, Neurofront Therapeutics, Neurolief, Nocira, Novartis, P Value Communications, Pain Insights, Inc, Palion Medical, Perfood, Pfizer, Pulmatrix, Putnam Associates, Rehaler, SAI MedPartners, Satsuma, Scilex, Slingshot Insights, Spherix Global Insights, Strategy Inc, Synapse Medical Communication, System Analytic, Taylor & Francis, Tegus, Teva, Theranica, Third Bridge, Tonix, Trinity Partners, Unity HA, Vial, and XOC. He has received salary from Dartmouth-Hitchcock Medical Center, Thomas Jefferson University, and Ki Health Partners.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"573"}}